ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO982

The Clinical Features and the Expression of suPAR and ApoA-1 in Focal Segmental Glomerulosclerosis

Session Information

Category: Pathology and Lab Medicine

  • 1501 Pathology and Lab Medicine: Basic

Authors

  • Lv, Jia, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
  • Gao, Wanwan, Huaihe Hospital of Henan University, Kai Feng, China
  • Xie, Liyi, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
  • Lan, Ping, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
Background

Our purpose is to explore whether serum and urine suPAR and ApoA-1 can be used as markers in patients with FSGS and to evaluate the value of serum and urine suPAR and ApoA-1 in predicting FSGS.

Methods

Subjects were selected by inclusion and exclusion criterias, divided into four groups: FSGS group, MN group, IgAN group and healthy group. Serum and urine samples were collected. Serum and urine suPAR levels and urine ApoA-1 levels were detected in each group by ELISA and analyzed. Their correlations with gender, age, urea nitrogen, creatinine, 24h urinary protein, eGFR, serum albumin, total cholesterol, and triglyceride were also analyzed.

Results

Serum suPAR levels of FSGS group were higher than the MN group, IgAN group and healthy control group (P < 0.05); in FSGS group, serum suPAR was positively correlated with serum creatinine (P < 0.05), negatively correlated with eGFR (P > 0.05). There was no significant correlation with gender, age, urea nitrogen, 24h urinary protein, serum albumin, total cholesterol and triglyceride (P > 0.05). Urine suPAR levels of FSGS group were higher than the MN group, IgAN group and healthy group (P < 0.05); in FSGS group, Urine suPAR was positively correlated with 24h urinary protein (P < 0.05), but no significant correlation with gender, age, Urea nitrogen, serum creatinine, eGFR,serum albumin, total cholesterol and triglyceride (P > 0.05).
Urine ApoA-1 levels of FSGS group, MN group and IgAN group were higher than healthy group(P < 0.05). There was no significant difference among FSGS group, MN group and IgAN group (P > 0.05). There was no significant correlation with dender, age, serum albumin, urea niteogen, serum creatinine, eGFR, total cholesterol and triglyceride (P > 0.05).
The best predictive value of serum suPAR for FSGS was 3280.28 pg/ml; the area under the curve of AUC was 0.831 (95%CI, 0.736-0.926), with sensitivity of 74.2% and specificity of 81%. The area under the curve of AUC for urine suPAR levels in predicting FSGS was 0.781 (95%CI, 0.673-0.890), with sensitivity of 71% and specificity of 77.8%. AUC for urinary APoA-1 in predicting FSGS was 0.483 (95%CI, 0.356-0.610) with sensitivity of 45.2% and specificity of 48.1%.

Conclusion

The value of serum suPAR level in predicting primary FSGS is higher than that of urine suPAR and ApoA-1. Serum suPAR is expected to be a serological marker for auxiliary diagnosis of FSGS.

Funding

  • Government Support - Non-U.S.